Pharmacological inhibition of VEGFR2 (SKLB1002) resulted in dramatic tumor shrinkage (Fig. 4a and b, P(day5th) = 0.436, P(day10th) = 0.406, P(day15th) = 0.266, P(day20th) = 0.071, P(day25th) = 0.050, P(day30th) = 0.045) and extensive necrosis (Fig. 4c). Here, KDR is linked to neoplasm.